Trials | Sample Size (n) | Centre | Key Inclusion Criteria | Follow-up (Months) | Primary Endpoint |
CTO-IVUS 2015 [35] | 201 | Multi-centre | CTO | 12 | Cardiac death: 0% versus 1%, p = 0.16 |
Tan et al. 2015 [36] | 61/62 | Single centre | Unprotected LM | 24 | MACE: 13.1% versus 29.3%, p = 0.031 |
IVUS-XPL 2015 [5] | 700 | Multi-centre | Long lesions (stent length > 28 mm | 12 | MACE: 2.9% versus 5.8%, p = 0.007 |
Zhang et al. 2016 [37] | 42 | Single centre | Small vessel disease (2.25 - 2.75 mm) | 12 | Post-PCI MLD: 2.77 ± 0.46 mm versus 2.53 + 0.21 mm, p < 0.0001 |
ULTIMATE 2018 [4] | 72 | Multi-centre | All corners | 12 | TVF: 2.9% vs 5.4%, p = 0.019 |